Big pharma and the problem of disease inflation

Area of Science:

• Medical Ethics
• Pharmaceutical Industry Influence
• Biomedical Research

Background:

• Critics highlight the pharmaceutical industry's negative impact on medical research and practice.
• Concerns include ghostwriting and market expansion tactics prioritizing profit over science.

Purpose of the Study:

• To analyze the intertwined goals of medical science and industry profit.
• To explore how this relationship redefines illness and creates ethical issues.
• To propose a more fundamental critique of biomedical science and corporate profit.

Main Methods:

• Literature review of critiques on pharmaceutical industry practices.
• Conceptual analysis of the relationship between medical science and corporate profit.
• Ethical examination of disease redefinition and expanded diagnostic criteria.

Main Results:

• Medical science increasingly aligns with corporate profit motives.
• Disease definitions and diagnostic thresholds are expanded to serve profit goals.
• Existing critiques on industry practices do not fully address these systemic ethical problems.

Conclusions:

• A fundamental re-evaluation of the nexus between biomedical science and corporate profit is necessary.
• Physicians, ethicists, and researchers must address the ethical implications of profit-driven medical science.
• Current critiques are insufficient to tackle the deep-seated issues arising from industry influence.